What is HC Wainwright’s Forecast for GANX FY2026 Earnings?

Gain Therapeutics, Inc. (NASDAQ:GANX) – Research analysts at HC Wainwright boosted their FY2026 earnings per share (EPS) estimates for shares of Gain Therapeutics in a research report issued on Monday, August 31st. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($0.49) per share for the year, up from their prior forecast of ($0.51). HC Wainwright currently has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Gain Therapeutics’ current full-year earnings is ($0.50) per share. HC Wainwright also issued estimates for Gain Therapeutics’ Q4 2026 earnings at ($0.12) EPS, Q1 2027 earnings at ($0.13) EPS, Q2 2027 earnings at ($0.13) EPS and FY2027 earnings at ($0.49) EPS.

Gain Therapeutics (NASDAQ:GANX) last released its earnings results on Tuesday, August 11th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.03.

Several other research analysts have also weighed in on the stock. Wall Street Zen upgraded shares of Gain Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, June 21st. Weiss Ratings downgraded shares of Gain Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 9th. Roth Capital reaffirmed a “buy” rating on shares of Gain Therapeutics in a research note on Tuesday, May 12th. Oppenheimer reiterated an “outperform” rating on shares of Gain Therapeutics in a report on Wednesday, May 27th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $5.00 target price on shares of Gain Therapeutics in a research report on Tuesday, August 11th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $7.50.

Gain Therapeutics Stock Down 1.7%

Shares of NASDAQ:GANX opened at $1.77 on Wednesday. The company has a current ratio of 4.36, a quick ratio of 4.36 and a debt-to-equity ratio of 0.02. The firm has a market cap of $77.24 million, a price-to-earnings ratio of -3.54 and a beta of 0.20. The stock’s 50-day moving average price is $1.85 and its two-hundred day moving average price is $1.94. Gain Therapeutics has a 12-month low of $1.53 and a 12-month high of $4.34.

Institutional Trading of Gain Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of GANX. GSA Capital Partners LLP bought a new position in Gain Therapeutics during the 2nd quarter worth approximately $1,283,000. Potomac Capital Management Inc. bought a new stake in shares of Gain Therapeutics during the 4th quarter valued at about $3,252,000. Apollon Wealth Management LLC lifted its holdings in shares of Gain Therapeutics by 33.7% in the 1st quarter. Apollon Wealth Management LLC now owns 26,500 shares of the company’s stock worth $51,000 after purchasing an additional 6,675 shares during the last quarter. Wealthspire Advisors LLC bought a new position in Gain Therapeutics in the 4th quarter worth about $54,000. Finally, JPMorgan Chase & Co. bought a new stake in Gain Therapeutics during the 3rd quarter valued at $47,000. 11.97% of the stock is owned by institutional investors.

About Gain Therapeutics

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.